SEC Form 4 · accession 0001013606-17-000151
ENDOLOGIX INC /DE/ · ELGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
John Onopchenko
Officer — Chief Operating Officer
Period of report
Oct 30, 2017
Accepted (ET)
Nov 1, 2017 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001013606
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Oct 30, 2017 | A | 56,604 | $0.00 | A | 56,604 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to PurchaseF2 | $5.30 | Oct 30, 2017 | A | 187,484 | A | Oct 30, 2018 | Oct 30, 2027 | Option to Purchase | 187,484 | 187,484 | D |
Explanation of responses
- F1Performance restricted stock unit award.
- F2Twenty-five percent of the options shall vest upon one year of service and the remaining balance will vest in equal monthly installments thereafter.